NexGel, Inc. has taken significant steps to strengthen its financial position and expand its operations through a recapitalization plan and a potential merger with Fountainhead LifeSciences. This strategic move is crucial for the company as it aims to solidify its presence in the surgical and medical instruments industry.
The filing, dated November 12, 2026, details the company's entry into several agreements, including Note Amendment and Conversion Agreements with holders of its convertible promissory notes and a Securities Purchase Agreement for a private placement of common stock and warrants. These transactions are part of a broader strategy to facilitate a merger with Fountainhead LifeSciences and its affiliates.
Background
NexGel, Inc. operates in the surgical and medical instruments and apparatus sector, as classified under SIC 3841. The company is publicly traded on the Nasdaq under the tickers NXGL and NXGLW. NexGel is based in Langhorne, Pennsylvania, and has undergone various filings recently, including an 8-K on October 12, 2026, regarding a reverse stock split.
What the Filing Says
The current filing reveals that on November 10, 2026, NexGel entered into agreements with holders of its convertible promissory notes totaling approximately $14.125 million. The agreements allow for the conversion of these notes into common stock at a price of $5.50 per share, contingent upon the completion of the merger with Fountainhead LifeSciences. The filing states, "The transactions are part of a recapitalization that is intended to be followed by a strategic business combination (the 'Merger')."
Furthermore, the filing indicates that the common stock issued to Fountainhead in the merger is expected to represent between 45% and 50% of the company's fully diluted shares, pending an independent valuation and fairness opinion.
Impact
This recapitalization and potential merger could significantly impact NexGel's operations and financial health. It may provide the company with necessary capital to expand its business and enhance its product offerings in the medical instruments sector. Additionally, the involvement of related parties, such as Brian Kieser, who is the Interim CEO and has interests in Fountainhead, adds a layer of complexity to the transaction.
What's Next
The filing does not specify the next steps following these agreements. However, the merger will require a definitive agreement, approval from the Special Committee and the Board of Directors, as well as necessary stockholder and Nasdaq approvals.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





